On June 18, Hengrui Pharmaceutical and Kailera Therapeutics of the United States jointly announced that the phase III clinical trial of the oral small molecule GLP-1 receptor agonist HRS-7535 in 810 adult subjects with type 2 diabetes in China had achieved positive top-line results. The 32-week main endpoint data showed that HbA1c decreased by 1.50% to 1.68% in the HRS-7535 dose group. Based on the positive front-line results of the OUTSTAND-1 and OUTSTAND-2 studies, Hengrui Pharmaceutical plans to submit a marketing application for HRS-7535 for the treatment of type 2 diabetes in China this year; the Chinese phase III clinical trial of HRS-7535 for overweight or obesity indications is ongoing, and relevant data will be disclosed in 2026. Kailera is currently conducting a global phase II clinical trial of KAI-7535 for obesity.
Zhitongcaijing · 2d ago
Share
Listen to the news
On June 18, Hengrui Pharmaceutical and Kailera Therapeutics of the United States jointly announced that the phase III clinical trial of the oral small molecule GLP-1 receptor agonist HRS-7535 in 810 adult subjects with type 2 diabetes in China had achieved positive top-line results. The 32-week main endpoint data showed that HbA1c decreased by 1.50% to 1.68% in the HRS-7535 dose group. Based on the positive front-line results of the OUTSTAND-1 and OUTSTAND-2 studies, Hengrui Pharmaceutical plans to submit a marketing application for HRS-7535 for the treatment of type 2 diabetes in China this year; the Chinese phase III clinical trial of HRS-7535 for overweight or obesity indications is ongoing, and relevant data will be disclosed in 2026. Kailera is currently conducting a global phase II clinical trial of KAI-7535 for obesity.
Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.
What's Trending